Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLENDID Trial
2025-522857-20-00Phase 2Authorised
- Sponsor
- Fraunhofer Institute for Translational Medicine and Pharmacology
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cizutamig in primary Sjögren’s syndrome (pSS), Autoimmune Myopathies, systemic sclerosis (SSc) and 1 more, sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology. Primary endpoint: Safety: CRS, ICANS, TEAEs and SAEs. Planned start Jan 2026; status: authorised.
02
Drugs
cizutamig
03
Conditions
primary Sjögren’s syndrome (pSS)Autoimmune Myopathiessystemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-522857-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522857-20-00.